Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06725758 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
A Phase 1 study, sponsored by Orion Corporation, Orion Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 315
- Enrollment target
NCT06725758 is a Phase 1 study that is actively recruiting participants, run by Orion Corporation, Orion Pharma. The registered enrollment target is 315 participants.
The verdict
NCT06725758, a Phase 1 study, is actively recruiting participants, sponsored by Orion Corporation, Orion Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 315 participants
- Enrollment target
Study Summary
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Interventions
- DRUG ODM-212
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2023-10-26 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06725758
The ClinicalTrials.gov registry entry for NCT06725758 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orion Corporation, Orion Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ODM-212 is the first listed.
NCT06725758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06725758 about?
NCT06725758 is a clinical study titled "A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours". Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
What is the current status of trial NCT06725758?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 315 participants. The study started on 2023-10-26. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT06725758?
The interventions under investigation include: ODM-212 (DRUG).
Who is sponsoring clinical trial NCT06725758?
This trial is sponsored by Orion Corporation, Orion Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.